12 results about "Upper urinary tract" patented technology

The invention relates to the technical field of biomedical detection, in particular to a urinary tract epithelium cancer detection marker composition based on ONECUT2 and DMRTA2 gene methylation, which comprises a CpG island region of an ONECUT2 gene, a CpG island region of a DMRTA2 gene and a kit for detecting urinary tract epithelium cancer. The CpG island region of the ONECUT2 gene is located in chr18: 57441548-57441674, and the CpG island region of the ONECUT2 gene is located in The CpG island region of the DMRTA2 gene is located in chr1: 50418714-50418823, and the CpG island region of the DMRTA2 gene is located in chr1: The kit for detecting urothelial carcinoma comprises a first primer pair and a first probe which are used for specifically detecting the methylation state of the CpG island region of the ONECUT2 gene in the claim 1, and a second primer pair and a second probe which are used for specifically detecting the methylation state of the CpG island region of the DMRTA2 gene. The urinary tract epithelium cancer detection marker composition based on ONECUT2 and DMRTA2 gene methylation has high sensitivity and high specificity, the sensitivity and the specificity are both 90% or above, early-stage and low-grade urinary tract epithelium cancer can be effectively detected, comprehensive coverage is achieved, and the urinary tract epithelium cancer detection marker composition is not only suitable for bladder cancer, but also suitable for upper urinary tract epithelium cancer such as renal pelvis cancer and ureter cancer.

Disclosed are compositions and methods for detecting, prognosing, grading, and treating a cancer such as, for example a bladder cancer including, but not limited to upper tract urothelial carcinoma (UTUC) using circulating tumor DNA (ctDNA).

The invention provides an application of an epidermal growth factor (EGF) in induction of apoptosis of an upper urinary tract epithelial carcinoma organ (UTUC), and belongs to the technical field of biomedicine. The invention relates to an application of an EGF (Epidermal Growth Factor) or EGFR (Epidermal Growth Factor Receptor) agonist in inducing The EGF induces apoptosis of the upper urinary tract epithelial cancer organoid by activating the STAT1-Caspase 3 pathway and up-regulating the expression level of the EGFR. In view of the fact that the upper urinary tract epithelium carcinoma organoid and the upper urinary tract epithelium carcinoma tissue are highly consistent in form and regulation mechanism, the technical scheme provided by the invention provides a new thought for the medicine for preventing and / or treating the upper urinary tract epithelium carcinoma.

The present application relates to the technical field of urinary calculus risk assessment, and particularly relates to a kind of upper urinary tract calculus postoperative recurrence risk assessment system based on multi-modal data.The present application trains neural network according to the training stone state in patient body and previous examination vector, determines the expected comprehensive load index of verification patient and the expected local load index under each mode using trained neural network, and obtains the prediction contribution weight of each mode;Using prediction contribution weight to adjust the expected local load index of all modes of the patient to be tested during follow-up, obtain the initial recurrence risk degree, and combine the life habits similarity and disease characteristics similarity of the patient to be tested and historical recurrence patients, obtain the calculus recurrence risk degree;Based on calculus recurrence risk degree, the recurrence risk of upper urinary tract calculus of the patient to be tested after operation is evaluated.The present application combines the static basic risk and dynamic disease risk of patient, reduces the influence of multi-modal data loss during follow-up on recurrence risk assessment.

The invention relates to the technical field of animal model construction methods, in particular to a construction method of a BBN (N-butyl-N-(4-hydroxybutyl) nitrosamine) induced upper urinary tract urothelial carcinoma animal model, according to the method, BBN (N-butyl-N-(4-hydroxybutyl) nitrosamine is used for conducting drinking water administration treatment at different stages and with different concentrations on a mouse, and the in-situ tumorigenesis upper urinary tract urothelial carcinoma animal model is formed through induction. According to the technical scheme, the problem that in the prior art, BBN can only induce urothelium carcinoma mainly including bladder cancer can be solved, the whole development stage of animal pelvis cancer and ureteral cancer from early abnormality to advanced cancerization can be observed through the upper urothelium carcinoma animal model constructed through the technical scheme, and the mechanism of different disease courses can be researched conveniently. The animal model is expected to further explain the occurrence and development mechanism of the upper urinary tract epithelial cancer and screen new therapeutic drugs, and has ideal application prospects.

To provide drug delivery devices and systems for delivery of a drug into the upper urinary tract of patients in need thereof.SOLUTION: A drug delivery device (1900) may be deployed directly into the renal pelvis via a patient's ureter, bladder, and urethra, and the drug delivery device can be wholly retained therein for local continuous, controlled release of a drug over an extended period.SELECTED DRAWING: Figure 19

The invention discloses an intelligent urine collecting device for urology department nursing, relates to the technical field of medical instruments, and aims to solve the technical problem that a patient is in a pathological urination mode for a long time due to the fact that an existing catheter cannot recognize and intervene detrusor sphincter coordination disorder in real time. One end of the catheter arranged in the bladder is provided with a catheterization port and an annular cavity, and the other end of the catheter is provided with an inflation extension tube communicated with an air source; the annular balloon is formed by expanding the annular cavity under the influence of an inflating medium; the inflating hole is formed in the catheter main body and is used for communicating the inflating extension tube with the annular cavity; the air bag internal pressure sensor is fixed on the inner wall of the annular cavity; a dual-pressure real-time monitoring system is constructed, and pressure change signals of detrusor contraction and sphincter areas in the urination period are accurately collected. The defect that the coordination state of the detrusor muscle and the sphincter cannot be sensed in the prior art is overcome, and therefore the upper urinary tract injury risk is effectively reduced.

The present invention provides a drug delivery device and system for delivering drugs to the upper urinary tract of patients who require them. [Solution] The drug delivery device is deployed directly into the renal pelvis 1902 via the patient's ureter 1940, bladder 1930, and urethra, and the drug delivery device can be held therein for localized, continuous, controlled release of the drug over a long period of time.

The utility model discloses a kind of balloon catheters for upper urinary tract perfusion, including catheter body and balloon;Catheter body is flexible tubular structure;The inside of catheter body is equipped with perfusion channel and inflation channel, inflation channel is parallel with perfusion channel and is not connected;Annular groove is provided on the outer wall of the proximal end of catheter body, balloon is fixed in annular groove;The front end of inflation channel is communicated with balloon, rear end extends to the outside of catheter body, for inflating balloon;The front end of balloon is trumpet-shaped, rear end gradually narrows, the front end part of balloon after inflation, rear end part respectively adhere to the inner wall of renal pelvis and ureter of upper urinary tract;Several convex points are arranged on the outer wall of the rear end of balloon.The balloon catheter of the utility model can better adhere to the anatomical structure of upper urinary tract, and the positioning effect of balloon catheter is enhanced, to solve the problems in the prior art.

The present invention relates to an in vitro method of classifying a patient that suffers from or is at risk of developing upper tract urothelial cancer, urothelial cancer or bladder cancer, said method comprising the steps of providing a liquid sample that has been obtained from a patient, and subjecting the sample to a first filtering step that withholds cells comprised in the sample yet lets smaller components like exosomes or macromolecules pass, so as to establish a cellular fraction and a first filtrate.

FIELD: medicine.SUBSTANCE: invention relates to operative urology, namely to surgical treatment of recurrent strictures of the pyeloureteral junction (PUJ) affecting the PUJ and ureter, when resection of the narrowed PUJ segment and performing an anastomosis of the renal pelvis with the ureter is impossible. The scarred narrowed segment of the ureterocalycopyeloanastomosis is isolated. Resection of the altered part of the ureter and the kidney parenchyma above the dilated lower calyx is performed. The posterior edges of the ureter and the lower calyx are connected with three interrupted sutures without tension, a stent is placed antegradely. A buccal mucosal graft is placed on the anterior part of the anastomosis.EFFECT: possibility to perform resection of the narrowed part of the ureter and restore patency of the upper urinary tract, form a wide lumen of the anastomosis between the lower calyx and the ureter by augmenting it with a buccal graft, which provides optimal urine outflow from the kidney, minimise the percentage of recurrence.1 cl, 3 dwg, 1 ex

Provided is a pharmaceutical composition that is for prevention or treatment of urinary tract organ cancer, causes no adverse side effects, can be continuously used for a long time, and is administered to the urinary tract organ by injection into the urinary tract organ cavity. A solution for injection into the urinary tract organ cavity contains D-allose. The inside of the urinary tract organ cavity is the inside of the upper urinary tract and the inside of the bladder. The solution is for injection therapy into the urinary tract organ cavity. The solution uses enhancement of sugar uptake into cancer cells of the urinary tract organ (for example, RT112, 253J, J82) by D-allose. The solution contains D-allose together with a pharmaceutically acceptable diluent or carrier. The solution is a pharmaceutical composition for prevention or treatment of urinary tract organ cancer.